WebDoctor Encyclopedia

Lung

Thymoma and thymic carcinoma

Thymoma and thymic carcinoma are rare tumours of the thymus, behind the breastbone. Thymomas are often linked with myasthenia gravis and other autoimmune conditions.

Medically reviewed Last reviewed October 27, 2026

What are thymoma and thymic carcinoma?

Thymoma and thymic carcinoma are rare cancers that start in the epithelial cells of the thymus. The thymus is a small organ that sits behind the breastbone, in the front part of the chest between the lungs (the anterior mediastinum). In childhood it trains T-lymphocytes, a type of white blood cell. After puberty it slowly shrinks and is largely replaced by fat, but some thymic tissue remains throughout life.

Together, these cancers are called thymic epithelial tumours (TETs). Although rare, they are the most common primary tumours of the anterior mediastinum in adults.

The two main groups behave very differently:

  • Thymoma usually grows slowly and is often confined to the thymus when found. Its cells look much like normal thymic cells, and it is frequently mixed with many lymphocytes. Thymomas are strongly linked with myasthenia gravis and other autoimmune conditions.
  • Thymic carcinoma is more aggressive. Its cells look clearly cancerous under the microscope, it invades nearby structures more often and it is more likely to spread to lymph nodes and distant organs. Autoimmune conditions are uncommon.

Both are treated mainly with surgery when the tumour can be removed completely. Radiotherapy and drug treatment are added for more advanced disease.

1. Epidemiology

Thymic epithelial tumours account for only a small fraction of all cancers, roughly 0.2-1.5% according to the US National Cancer Institute. Each year they are diagnosed in about 1.3 to 3.2 people per million, and thymic carcinoma makes up about one fifth of all cases.

The average age at diagnosis is 50-60 years, but these tumours can occur at any age, including, rarely, in children.

Feature Thymoma Thymic carcinoma
Share of thymic epithelial tumours About 80% About 20%
Typical age at diagnosis Most often 40-70 years; rare in children and young adults Similar, middle-aged and older adults
Sex No consistent difference between men and women Somewhat more common in men
Autoimmune conditions Common, especially myasthenia gravis (about 30-50% of patients) Rare
Usual behaviour Slow-growing; spreads mainly within the chest Faster-growing; more often spreads to lymph nodes and distant organs

2. Causes and Risk Factors

The cause of thymic epithelial tumours is not known. Unlike many other cancers, they have no established links with smoking, diet, alcohol or occupational exposures, and they are not usually inherited.

Research on the tumours themselves has shown some typical genetic changes:

  • GTF2I mutation: a specific change in the GTF2I gene is found in most type A and type AB thymomas but is uncommon in type B thymomas and rare in thymic carcinoma. It is linked with the more indolent forms of the disease.
  • Thymic carcinoma carries more genetic damage overall, including changes in TP53 and loss of CDKN2A. A small minority have KIT mutations.

Rare inherited conditions, mainly multiple endocrine neoplasia type 1 (MEN1), can increase the risk. MEN1 is more strongly linked with thymic neuroendocrine tumours (thymic carcinoids), which arise in the same location but are a separate disease and are not covered in detail here.

3. The Thymus and the Immune Connection

The thymus is where young T-cells learn to tell the body’s own tissues apart from foreign invaders. Thymoma cells can keep some of this “teaching” function, but they do it badly. As a result, T-cells that react against the body’s own tissues can escape into the bloodstream.

This explains why thymoma, more than almost any other tumour, is associated with autoimmune (paraneoplastic) disorders. These conditions can appear before the tumour is found, at the same time, or even years after it has been removed.

The best-known example is myasthenia gravis, in which antibodies attack the acetylcholine receptors where nerves meet muscles. Other important associations are listed in the Symptoms section below.

4. WHO Classification

The World Health Organization (WHO) classification, most recently updated in 2021, divides thymomas into types according to the shape of the tumour cells and the number of lymphocytes. Thymic carcinomas are classified separately by their microscopic type.

WHO type What the pathologist sees Typical behaviour
A Bland spindle-shaped or oval epithelial cells, few lymphocytes Usually indolent
AB Areas of type A mixed with lymphocyte-rich areas Usually indolent
B1 Many lymphocytes, resembling normal thymic cortex; scattered epithelial cells Low risk
B2 More plump epithelial cells, still with many lymphocytes Intermediate risk
B3 Sheets of mildly atypical epithelial cells, few lymphocytes Higher risk of invasion and recurrence
Thymic carcinoma Clearly malignant cells; squamous cell carcinoma is the most common type. Rarer types include basaloid, lymphoepithelial, adenocarcinoma, NUT carcinoma and undifferentiated carcinoma Aggressive

The WHO also recognises a few rare thymoma variants, such as micronodular thymoma with lymphoid stroma and metaplastic thymoma.

All thymomas are now regarded as malignant, because even small, encapsulated tumours can occasionally recur or spread. In general, types A, AB and B1 have the best outlook, while B2, B3 and especially thymic carcinoma carry a higher risk.

5. How does it look?

Thymic tumours are hidden inside the chest, so they cannot be seen or felt from the outside. Their appearance is described on scans, during surgery and under the microscope.

5.1 On scans

On a chest X-ray, a large thymic tumour may appear as a widening of the central shadow of the chest or a rounded mass at the front of the mediastinum. Smaller tumours are often invisible on X-ray and are found on CT scans done for other reasons.

On CT, a thymoma typically looks like a smooth, round or lobulated mass in front of the heart and great vessels. Some contain cysts or calcifications.

Features that suggest a more aggressive tumour, such as a type B3 thymoma or a thymic carcinoma, include:

  • An irregular outline and uneven internal texture, with areas of dead tissue (necrosis)
  • Growth into fat, the pericardium (the sac around the heart), lung or large blood vessels
  • Small deposits on the pleura (lining of the lung) or pericardium, or fluid around the lung or heart
  • Enlarged lymph nodes or spread to distant organs, which is more typical of thymic carcinoma

MRI can help show whether the tumour is invading the heart or major vessels, and can help distinguish a thymoma from a normal or enlarged (hyperplastic) thymus. On PET-CT, thymic carcinomas and higher-risk thymomas usually take up more of the tracer than low-risk thymomas. PET-CT is mainly used for staging when carcinoma is suspected.

5.2 During surgery

Many thymomas are well defined and enclosed in a thin fibrous capsule. When cut, they are typically firm, tan to grey and divided into lobules by fibrous bands, sometimes with cysts.

Invasive thymomas and thymic carcinomas have less clear borders. They may stick to or grow into the surrounding fat, pleura, pericardium, lung or blood vessels. Thymic carcinomas are often larger, harder and show areas of bleeding or necrosis.

5.3 Under the microscope

The pathologist looks at the shape of the epithelial cells and the proportion of lymphocytes to assign the WHO type. Special stains (immunohistochemistry) support the diagnosis.

  • The epithelial cells of both thymomas and squamous thymic carcinomas are usually positive for markers such as cytokeratins and p63/p40.
  • In type AB and type B thymomas, the lymphocytes are mostly immature T-cells that stain for TdT. These immature T-cells are usually absent in type A thymoma and in thymic carcinoma.
  • About 80% of thymic carcinomas stain positive for CD5 and CD117 (KIT). This helps confirm that a carcinoma in the mediastinum started in the thymus rather than, for example, in the lung.

6. Symptoms

About a third of people with a thymic tumour have no symptoms at all. Their tumour is found by chance on a chest scan. When symptoms do occur, they come from the tumour pressing on nearby structures, from an associated autoimmune condition, or, less often, from spread of the cancer.

6.1 Symptoms from the tumour itself

  • Chest pain or pressure behind the breastbone
  • Persistent cough
  • Shortness of breath, from pressure on the airways, fluid around the lungs or paralysis of the diaphragm if the phrenic nerve is involved
  • Hoarseness, if the nerve to the voice box is affected
  • Difficulty swallowing, which is uncommon
  • Superior vena cava syndrome: swelling of the face, neck and arms, prominent veins on the chest and headaches. This happens when the tumour presses on the large vein returning blood from the upper body, and is more typical of invasive tumours.

6.2 Autoimmune (paraneoplastic) conditions

These are a hallmark of thymoma and can be the first sign of the disease.

Condition How often (in thymoma) Typical signs
Myasthenia gravis About 30-50% of patients Drooping eyelids, double vision, difficulty chewing, swallowing or speaking, and muscle weakness that worsens with use and improves with rest
Good syndrome (low antibody levels, hypogammaglobulinaemia) About 5%; some series report higher rates Repeated chest and sinus infections, chronic diarrhoea and unusual (opportunistic) infections
Pure red cell aplasia About 5% Severe anaemia with tiredness and paleness, because the bone marrow stops making red blood cells
Other autoimmune disorders Less common For example lupus, inflammation of muscles (myositis) or heart muscle (myocarditis), autoimmune hepatitis, thyroid disease and some skin conditions

Doctors often find a thymoma because a person with newly diagnosed myasthenia gravis has a chest CT, which is a routine part of the work-up. In a middle-aged adult, myasthenia gravis together with a mass in the front of the chest strongly suggests a thymoma.

6.3 Symptoms of advanced disease

  • Tiredness, loss of appetite, weight loss, fever or night sweats
  • Breathlessness from fluid around the lungs or heart
  • Bone pain or other symptoms from distant spread, which is more typical of thymic carcinoma

6.4 When to see a doctor

See a doctor promptly if you have chest pain, cough or breathlessness that does not go away, or swelling of the face and neck. Muscle weakness that gets worse during the day, drooping eyelids or double vision also need prompt assessment.

7. Diagnosis

7.1 Imaging

A contrast-enhanced CT scan of the chest is the main test. MRI and PET-CT are used in selected cases, as described above.

7.2 Blood tests

  • Acetylcholine receptor antibodies, to look for myasthenia gravis. This is important before any operation, because undiagnosed myasthenia can cause serious breathing problems after anaesthesia.
  • Blood count and immunoglobulin levels, to check for pure red cell aplasia and Good syndrome
  • Alpha-fetoprotein (AFP) and beta-hCG, especially in young men, to rule out a germ cell tumour, which can arise in the same location

7.3 Ruling out other causes

Other conditions that can cause a mass in the front of the chest include lymphoma, germ cell tumours, an enlarged thyroid (goitre) extending into the chest and benign enlargement of the thymus (thymic hyperplasia). Telling them apart matters because their treatment is very different.

7.4 Biopsy

If the scan strongly suggests an early, removable thymoma, surgeons may proceed directly to an operation without a biopsy. The diagnosis is then confirmed on the removed tumour.

When the tumour looks advanced, cannot be removed, or another diagnosis such as lymphoma is possible, a core needle biopsy guided by CT or a small surgical biopsy is performed. Biopsy routes that pass through the pleural space are avoided where possible, because of the risk of spreading tumour cells.

8. Staging

Staging describes how far the tumour has spread and is the most important guide to treatment and outlook.

8.1 Masaoka-Koga staging

This surgical-pathological system has been used for decades and is still widely quoted.

Stage Description
I Completely encapsulated tumour, with no invasion through the capsule
IIA Microscopic invasion through the capsule
IIB Macroscopic invasion into surrounding fat, or tumour adherent to (but not through) the mediastinal pleura or pericardium
III Macroscopic invasion of neighbouring organs, such as the pericardium, lung or great vessels
IVA Tumour deposits on the pleura or pericardium
IVB Spread through lymph vessels or the bloodstream to lymph nodes or distant organs

In one classic surgical series of thymoma, five-year survival was about 96% for stage I, 86% for stage II, 69% for stage III and 50% for stage IV.

8.2 TNM staging (8th edition, AJCC/UICC)

Since 2017, thymic epithelial tumours also have an official TNM classification. It is based on the IASLC/ITMIG staging project and applies to both thymoma and thymic carcinoma.

Category Definition
T1a / T1b Tumour encapsulated or extending into mediastinal fat; T1b if it directly invades the mediastinal pleura
T2 Invasion of the pericardium
T3 Invasion of the lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall or pulmonary vessels outside the pericardium
T4 Invasion of the aorta or its arch branches, pulmonary artery inside the pericardium, heart muscle, trachea or oesophagus
N1 / N2 Spread to anterior lymph nodes around the thymus (N1), or to deep chest or neck lymph nodes (N2)
M1a / M1b Separate pleural or pericardial nodules (M1a), or nodules within the lung or distant organ spread (M1b)

The stage groups are:

Stage TNM groups
I T1 N0 M0
II T2 N0 M0
IIIA T3 N0 M0
IIIB T4 N0 M0
IVA Any T with N1, or M1a
IVB Any T with N2, or M1b

9. Treatment

Thymic tumours are rare, so treatment is best planned by an experienced multidisciplinary team. This team includes thoracic surgeons, oncologists, radiation oncologists, pathologists and, where needed, neurologists.

9.1 Surgery

Complete surgical removal is the cornerstone of treatment and the strongest factor for cure.

  • The standard operation is a total thymectomy: removal of the tumour together with the whole thymus and the surrounding fat. Traditionally this is done through the breastbone (median sternotomy).
  • For small, early-stage tumours, experienced centres also use minimally invasive (thoracoscopic or robotic) surgery.
  • For locally advanced tumours, surgeons may need to remove part of the lung, pericardium, phrenic nerve or a large vein to achieve complete resection (R0), meaning no tumour is left behind.
  • Nearby lymph nodes are removed for staging. This is especially important in thymic carcinoma, which spreads to lymph nodes far more often than thymoma.
  • Myasthenia gravis must be well controlled before surgery to reduce the risk of breathing problems afterwards.

9.2 Radiotherapy

Radiotherapy after surgery (postoperative radiotherapy) is not needed after complete removal of a stage I thymoma. After complete removal of a stage II thymoma it is not routinely recommended, but may be considered for higher-risk types (B2, B3) or more extensive invasion.

According to European (ESMO) guidance, postoperative radiotherapy is recommended for completely removed stage III-IVA thymoma and for any tumour that could not be removed completely. For thymic carcinoma it is optional in stage I, should be considered in stage II and is recommended in stage III-IVA.

Typical doses are 45-50 Gy after complete removal and 50-54 Gy when microscopic tumour remains at the edges. About 60 Gy is used for visible residual tumour or when radiotherapy is the main treatment.

Radiotherapy, often combined with chemotherapy, can also be the main treatment when surgery is not possible. Modern techniques such as intensity-modulated radiotherapy (IMRT) and, in some centres, proton therapy help protect the heart and lungs.

9.3 Chemotherapy

Chemotherapy is used:

  • Before surgery (induction or neoadjuvant chemotherapy), to shrink a large, invasive tumour so it can be removed completely
  • For tumours that cannot be removed, often combined with radiotherapy
  • For recurrent or metastatic disease

Commonly used regimens include:

Regimen Drugs Mainly used for
CAP Cisplatin, doxorubicin (Adriamycin), cyclophosphamide Thymoma
ADOC Cisplatin, doxorubicin, vincristine, cyclophosphamide Thymoma
Carboplatin-paclitaxel Carboplatin, paclitaxel A common first choice for thymic carcinoma; also used for thymoma
Cisplatin-etoposide Cisplatin, etoposide Alternative for both

Thymomas respond to chemotherapy more often than thymic carcinomas. In a phase II trial of carboplatin-paclitaxel, about 43% of thymomas and 22% of thymic carcinomas shrank significantly.

9.4 Targeted therapy and immunotherapy

For thymic carcinoma that has progressed after chemotherapy, further options include:

  • Lenvatinib, a tablet that blocks several growth-signal receptors, including those involved in blood vessel formation. In the Japanese phase II REMORA trial, the tumour shrank in about 38% of patients. It is approved for thymic carcinoma in Japan, but its use elsewhere is usually off-label.
  • Sunitinib, a similar multi-target drug. In a phase II trial it produced responses in about a quarter of patients with thymic carcinoma but rarely in thymoma. It is used off-label.
  • Everolimus, an mTOR inhibitor, which has shown activity in both thymoma and thymic carcinoma
  • Octreotide, with or without prednisone, for some thymomas that show uptake on an octreotide scan

Immunotherapy with checkpoint inhibitors such as pembrolizumab shrinks about one in five thymic carcinomas, and some responses last for years. However, people with thymic tumours have a much higher risk of severe immune side effects than people with other cancers. These include myocarditis (inflammation of the heart muscle), myositis, hepatitis and new or worsening myasthenia gravis.

For this reason, immunotherapy is generally reserved for thymic carcinoma after chemotherapy, with close monitoring. In thymoma, it is used only with great caution, ideally within clinical trials.

9.5 Treating the autoimmune conditions

  • Myasthenia gravis is treated with pyridostigmine, steroids and other immunosuppressants. Intravenous immunoglobulin or plasma exchange is used for severe flares and before surgery. Removing the thymoma does not always cure myasthenia, which may persist or, rarely, appear for the first time after surgery.
  • Pure red cell aplasia usually needs immunosuppressive treatment such as ciclosporin; thymectomy alone often does not correct it.
  • Good syndrome is treated with regular immunoglobulin replacement and prompt treatment of infections. Antibody levels usually do not recover after the tumour is removed.

10. Prognosis

The outlook depends mainly on the stage, on whether the tumour was completely removed, and on the WHO type.

  • Thymoma: most people with early-stage thymoma that has been completely removed are cured or live for many years. Types A, AB and B1 have the best outlook. B2 and B3 tumours recur more often.
  • Thymic carcinoma: the outlook is less favourable, because the disease is often advanced at diagnosis. It is best when the tumour can be removed completely. According to the US National Cancer Institute, five-year survival is about 36% for inoperable, locally advanced thymic carcinoma and about 24% for metastatic thymic tumours.

Recurrence occurs in roughly 10-15% of people after surgery, on average about five years later, and occasionally after more than ten years. Recurrences are often within the chest (pleura or pericardium). They are treated in the same way as a new tumour, and repeat surgery is often possible.

People who have had a thymoma also have a somewhat increased risk of developing other cancers later in life.

11. Follow-up and Living with a Thymic Tumour

Because of the risk of late recurrence, follow-up lasts many years. European (ESMO) guidance suggests a first chest CT scan 3-4 months after surgery, followed by regular scans:

  • For completely removed stage I-II thymoma: a scan every year for five years, then every two years
  • For stage III-IV thymoma, thymic carcinoma or incompletely removed tumours: a scan every six months for two years, then yearly
  • Follow-up may continue for 10 to 15 years.

Everyday life after treatment is often normal, especially for people with early-stage thymoma. Some practical points can help:

  • People with myasthenia gravis should carry information about their condition. Some medicines, including certain antibiotics, muscle relaxants and beta-blockers, can worsen myasthenia, so they should always tell doctors and pharmacists about it.
  • New autoimmune conditions can appear years after treatment, so new symptoms such as muscle weakness should be reported.
  • People with Good syndrome need early treatment of infections and should discuss vaccinations with their doctor. Live vaccines are usually avoided.
  • Rare cancer networks and myasthenia gravis patient organisations offer reliable information and peer support.

12. Conclusion

Thymoma and thymic carcinoma are rare tumours of the thymus that share a location but differ greatly in behaviour. Thymoma is usually slow-growing and closely linked with autoimmune diseases, above all myasthenia gravis. Thymic carcinoma is more aggressive and more likely to spread.

For both, complete surgical removal offers the best chance of cure. Radiotherapy and chemotherapy are added for more advanced disease. For thymic carcinoma that returns, targeted drugs such as lenvatinib and sunitinib, and carefully selected immunotherapy, offer further options.

Because these tumours are rare and recurrences can occur many years later, care in an experienced centre and long-term follow-up are essential.

Resources

  1. Marx, A. et al. (2022) ‘The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors?’, Journal of Thoracic Oncology, 17(2), pp. 200-213.
  2. Detterbeck, F.C. et al. (2014) ‘The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors’, Journal of Thoracic Oncology, 9(9 Suppl. 2), pp. S65-S72.
  3. Girard, N. et al. (2015) ‘Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 26(Suppl. 5), pp. v40-v55.
  4. Petrini, I. et al. (2014) ‘A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors’, Nature Genetics, 46(8), pp. 844-849.
  5. Lemma, G.L. et al. (2011) ‘Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma’, Journal of Clinical Oncology, 29(15), pp. 2060-2065.
  6. Thomas, A. et al. (2015) ‘Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial’, The Lancet Oncology, 16(2), pp. 177-186.
  7. Sato, J. et al. (2020) ‘Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial’, The Lancet Oncology, 21(6), pp. 843-850.
  8. Giaccone, G. et al. (2018) ‘Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study’, The Lancet Oncology, 19(3), pp. 347-355.
  9. National Cancer Institute (2026) Thymoma and Thymic Carcinoma Treatment (PDQ®) – Health Professional Version. Available at: https://www.cancer.gov/types/thymus-cancer/hp/thymoma-treatment-pdq (Accessed: October 2026).
  10. American Cancer Society (2026) Thymus Cancer. Available at: https://www.cancer.org/cancer/types/thymus-cancer.html (Accessed: October 2026).

Prepared by the editorial team, October 2026.